

# Susan M Ott

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9173937/publications.pdf>

Version: 2024-02-01

49  
papers

11,995  
citations

331259

21  
h-index

253896

43  
g-index

49  
all docs

49  
docs citations

49  
times ranked

9462  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee. <i>Journal of Bone and Mineral Research</i> , 1987, 2, 595-610.	3.1	4,558
2	Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. <i>Lancet</i> , The, 1996, 348, 1535-1541.	6.3	3,496
3	Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2-17.	3.1	2,023
4	Incidence of atypical nontraumatic diaphyseal fractures of the femur. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2544-2550.	3.1	370
5	The Prevalence of Bone Aluminum Deposition in Renal Osteodystrophy and Its Relation to the Response to Calcitriol Therapy. <i>New England Journal of Medicine</i> , 1982, 307, 709-713.	13.9	352
6	Cortical or Trabecular Bone: What's the Difference?. <i>American Journal of Nephrology</i> , 2018, 47, 373-375.	1.4	135
7	Mineral Changes in Osteoporosis. <i>Clinical Orthopaedics and Related Research</i> , 2006, 443, 28-38.	0.7	127
8	Bone Mineral, Histomorphometry, and Body Composition in Adults with Growth Hormone Receptor Deficiency. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 415-421.	3.1	102
9	Bone Histomorphometric and Biochemical Marker Results of a 2-Year Placebo-Controlled Trial of Raloxifene in Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 341-348.	3.1	97
10	Bone Structure in Patients with Low Bone Mineral Density With or Without Vertebral Fractures. <i>Journal of Bone and Mineral Research</i> , 2000, 15, 1368-1375.	3.1	93
11	When bone mass fails to predict bone failure. <i>Calcified Tissue International</i> , 1993, 53, S7-S13.	1.5	87
12	Cystatin C, Renal Function, and Incidence of Hip Fracture in Postmenopausal Women. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1434-1441.	1.3	70
13	Histomorphometric Measurements of Bone Turnover, Mineralization, and Volume. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, S151-S156.	2.2	57
14	What is the optimal duration of bisphosphonate therapy?. <i>Cleveland Clinic Journal of Medicine</i> , 2011, 78, 619-630.	0.6	52
15	Therapy for patients with CKD and low bone mineral density. <i>Nature Reviews Nephrology</i> , 2013, 9, 681-692.	4.1	34
16	Ethnic differences in bone and mineral metabolism in healthy people and patients with CKD. <i>Kidney International</i> , 2014, 85, 1283-1289.	2.6	28
17	Bone strength: more than just bone density. <i>Kidney International</i> , 2016, 89, 16-19.	2.6	27
18	<i>Journal of Bone and Mineral Research</i> . <i>Journal of Bone and Mineral Research</i> , 1993, 8, S597-S606.	3.1	26

#	ARTICLE	IF	CITATIONS
19	Bisphosphonate safety and efficacy in chronic kidney disease. <i>Kidney International</i> , 2012, 82, 833-835.	2.6	26
20	Dâ€Lactate and Metabolic Bone Disease in Patients Receiving Longâ€Term Parenteral Nutrition. <i>Journal of Parenteral and Enteral Nutrition</i> , 1989, 13, 132-135.	1.3	25
21	Journal of Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 1991, 6, S71-S76.	3.1	25
22	Histomorphometric Analysis of Bone Remodeling. , 2002, , 303-319.		20
23	Bone disease in CKD. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 376-381.	1.0	15
24	Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2015, 28, 363-369.	0.7	15
25	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14
26	Renal Osteodystrophyâ€Time for Common Nomenclature. <i>Current Osteoporosis Reports</i> , 2017, 15, 187-193.	1.5	12
27	Bones and the sex hormones. <i>Kidney International</i> , 2018, 94, 239-242.	2.6	12
28	Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women. <i>JAMA Network Open</i> , 2020, 3, e2025190.	2.8	12
29	Navel Jewelry Artifacts and Intravertebral Variation in Spine Bone Densitometry in Adolescents and Young Women. <i>Journal of Clinical Densitometry</i> , 2009, 12, 84-88.	0.5	11
30	Bone cells, sclerostin, and FGF23: whatâ€™s bred in the bone will come out in the flesh. <i>Kidney International</i> , 2015, 87, 499-501.	2.6	11
31	Role of proton receptor OGR1 in bone response to metabolic acidosis?. <i>Kidney International</i> , 2016, 89, 529-531.	2.6	11
32	Bone formation periods studied with triple tetracycline labels in women with postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1993, 8, 443-450.	3.1	10
33	Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. <i>Kidney International</i> , 2021, 100, 502-505.	2.6	10
34	Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. <i>BMC Musculoskeletal Disorders</i> , 2020, 21, 801.	0.8	6
35	A comparison of self-reported oral contraceptive use and automated pharmacy data in perimenopausal and early postmenopausal women. <i>Annals of Epidemiology</i> , 2015, 25, 55-59.	0.9	5
36	Long-term bisphosphonates: primum non nocere. <i>Menopause</i> , 2016, 23, 1159-1161.	0.8	4

#	ARTICLE	IF	CITATIONS
37	What Are the Most Common Errors in the Management of Renal Osteodystrophy?. <i>Seminars in Dialysis</i> , 1989, 2, 145-146.	0.7	3
38	Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 719-723.	0.5	3
39	Renal insufficiency and bone loss. <i>Current Opinion in Rheumatology</i> , 2019, 31, 394-399.	2.0	2
40	Letter re: Alendronate in Anorexia Nervosa. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5508-5508.	1.8	2
41	Consider the Bisphosphonate Dose. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1-2.	3.1	2
42	Does Estrogen Play a Role in Renal Osteodystrophy?. <i>Seminars in Dialysis</i> , 1995, 8, 4-11.	0.7	1
43	Debating the duration of bisphosphonate therapy. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2013, 26, 64-65.	0.1	1
44	Osteoporosis Associated with Chronic Kidney Disease. , 2013, , 1387-1424.		1
45	Determinants of Oral Bisphosphonate Use Beyond 5 Years. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 197-202.	0.5	1
46	Osteoporosis associated with chronic kidney disease. , 2021, , 1325-1380.		1
47	Structural and Metabolic Assessment of Bone. <i>Handbook of Experimental Pharmacology</i> , 2020, 262, 369-396.	0.9	0
48	Not etched in bone: the role of osteoclast proton-sensing receptors. <i>Kidney International</i> , 2021, 99, 542-545.	2.6	0
49	Renal Osteodystrophy and Bone Biopsy. <i>Nephrology Self-assessment Program: NephSAP</i> , 2020, 19, 215-225.	3.0	0